| Quarterly Financials | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 681 | 916 | 852 | 895 | 935 | 1,216 | 1,132 | 1,109 | 1,168 | 931 | 1,110 | 1,000 | 824 | 1,246 | 1,427 | 1,583 | 1,580 | 1,453 | 1,466 | 1,443 | 1,469 | 1,563 | 1,571 | 1,759 | 1,854 |
| Expenses | 395 | 472 | 534 | 595 | 560 | 718 | 704 | 714 | 755 | 587 | 748 | 649 | 673 | 915 | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 | 1,138 | 1,173 | 1,285 | 1,230 |
| EBITDA | 286 | 445 | 318 | 299 | 375 | 498 | 428 | 395 | 414 | 344 | 363 | 351 | 151 | 332 | 377 | 394 | 401 | 316 | 357 | 418 | 392 | 425 | 398 | 474 | 625 |
| Operating Profit % | 38 % | 47 % | 36 % | 31 % | 37 % | 38 % | 35 % | 33 % | 32 % | 32 % | 28 % | 31 % | 14 % | 24 % | 24 % | 23 % | 23 % | 19 % | 21 % | 26 % | 24 % | 24 % | 21 % | 24 % | 29 % |
| Depreciation | 24 | 24 | 25 | 25 | 25 | 25 | 26 | 28 | 31 | 35 | 37 | 38 | 38 | 65 | 81 | 105 | 93 | 92 | 94 | 96 | 96 | 101 | 106 | 108 | 109 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 2 | 5 | 6 | 5 | 10 | 6 | 6 | 23 | 7 | 12 | 8 | 4 | 10 |
| Profit Before Tax | 262 | 420 | 293 | 273 | 349 | 472 | 401 | 366 | 381 | 309 | 324 | 311 | 111 | 261 | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 |
| Tax | 67 | 106 | 74 | 69 | 89 | 121 | 99 | 93 | 95 | 79 | 83 | 79 | 33 | 67 | 96 | 91 | 106 | 75 | 93 | 95 | 102 | 97 | 100 | 101 | 139 |
| Net Profit | 195 | 314 | 219 | 204 | 260 | 351 | 302 | 273 | 286 | 229 | 241 | 232 | 79 | 194 | 194 | 192 | 192 | 144 | 164 | 205 | 187 | 216 | 184 | 262 | 367 |
| EPS in ₹ | 12.57 | 20.24 | 14.12 | 12.83 | 15.93 | 21.41 | 18.37 | 16.62 | 17.40 | 13.93 | 14.65 | 14.08 | 4.78 | 11.79 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.26 |
Gland Pharma
Gland Pharma
2,232.30
-44.70
(-1.96%)
Market Cap
36,778.60 Cr
PE Ratio
35.84
Volume
2,55,715.00
Day High - Low
2,305.90 - 2,222.00
52W High-Low
2,396.00 - 1,573.60
There are new updates from the company1 day ago
View
Key Fundamentals
Market Cap
36,778.60 Cr
EPS
62.35
PE Ratio
35.84
PB Ratio
3.55
Book Value
627.91
EBITDA
1,605.20
Dividend Yield
0.89 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
7.63
Debt to Equity
0.04
Analyst Rating and Forecast
- By Refinitiv from15 analysts
Actual
Company News
View All News
Gland Pharma schedules investor meets
8 days ago
8 days agoGland Pharma Limited will meet investors on June 1 and June 8, 2026. Meetings include Carnelian Asset Management and ICICI Securities.
Gland Pharma: ₹15.48 Cr Block Trade on NSEMay 20, 2026
Gland Pharma sees a block trade of ~68,258 shares on NSE at ₹2267.30 per share, aggregating to ₹15.48 crores.
Gland Pharma announces analyst and institutional investor meetings on May 21, 27, and 29, 2026, under SEBI Regulation 30 disclosure requirements.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,788.50 | #1 4,29,121.10 | 37.30 | #1 58,220.10 | 6.38 | #1 11,565 | 25.80 | 44.37 | |
6,576.50 | 1,74,585.40 | 67.97 | 10,560.00 | 8.73 | 2,520 | 13.44 | 46.75 | |
4,368.50 | 1,47,849.90 | 69.16 | 13,886.20 | 20.34 | 2,138 | -26.91 | 50.11 | |
1,375.20 | 1,11,086.00 | 28.76 | 27,711.70 | -2.46 | 3,783 | -55.32 | 52.65 | |
1,076.60 | 1,08,331.20 | 21.14 | 26,719.70 | 13.65 | 5,242 | 7.82 | 68.91 | |
1,263.30 | 1,05,440.50 | 25.35 | 33,593.30 | -0.44 | 3,998 | -86.05 | 41.47 | |
2,261.20 | 1,03,346.60 | #1 19.30 | 27,487.50 | 19.98 | 5,345 | #1 87.72 | 45.17 | |
2,369.50 | 97,814.20 | 50.52 | 14,277.60 | 12.03 | 1,750 | 31.75 | 50.42 | |
1,440.40 | 83,658.70 | 23.88 | 33,384.70 | 3.21 | 3,376 | 1.99 | 48.90 | |
1,394.30 | 75,272.20 | 84.57 | 6,812.90 | #1 21.03 | 884 | 21.18 | 76.00 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
10.30 %
Net Income Growth
43.98 %
Cash Flow Change
-8.23 %
ROE
-13.79 %
ROCE
-8.55 %
EBITDA Margin (Avg.)
-6.45 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,661 | 11,225 | 12,511 |
| Fixed Assets | 968 | 954 | 1,502 | 1,571 | 3,947 | 4,147 | 4,541 |
| Current Assets | 2,846 | 5,124 | 5,852 | 6,901 | 5,645 | 6,783 | 7,527 |
| Capital Work in Progress | 189 | 338 | 191 | 177 | 238 | 151 | 342 |
| Investments | 0 | 0 | 155 | 0 | 0 | 0 | 1,744 |
| Other Assets | 2,930 | 5,204 | 5,986 | 7,030 | 6,477 | 6,927 | 0 |
| Total Equity & Liabilities | 4,086 | 6,496 | 7,834 | 8,778 | 10,661 | 11,225 | 12,511 |
| Current Liabilities | 359 | 513 | 582 | 729 | 1,398 | 1,565 | 1,608 |
| Non Current Liabilities | 81 | 80 | 94 | 90 | 539 | 509 | 545 |
| Total Equity | 3,646 | 5,903 | 7,158 | 7,959 | 8,724 | 9,151 | 10,358 |
| Reserve & Surplus | 3,631 | 5,887 | 7,141 | 7,942 | 8,707 | 9,134 | 10,342 |
| Share Capital | 16 | 16 | 16 | 17 | 17 | 17 | 17 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -67 | 323 | -174 | 1,590 | -1,552 | 2,199 |
| Investing Activities | -761 | -1,520 | -999 | 1,211 | -1,749 | 1,718 |
| Operating Activities | 701 | 605 | 791 | 364 | 997 | 915 |
| Financing Activities | -7 | 1,239 | 35 | 15 | -799 | -434 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 58.25 % | 58.14 % | 58.02 % | 58.00 % | 58.00 % | 57.87 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.00 % | 4.91 % | 0.00 % | 3.59 % | 6.88 % | 4.47 % | 5.04 % | 6.90 % | 7.39 % | 7.91 % | 7.58 % | 7.30 % |
| DIIs | 10.69 % | 11.57 % | 11.39 % | 11.21 % | 11.94 % | 16.71 % | 20.58 % | 23.13 % | 23.23 % | 23.38 % | 22.45 % | 23.14 % | 25.23 % | 32.83 % | 35.37 % | 34.80 % | 33.27 % | 32.85 % | 32.64 % | 32.98 % | 33.35 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.30 % | 3.72 % | 3.77 % | 3.58 % | 3.69 % | 3.70 % | 3.77 % | 4.02 % | 4.26 % | 5.60 % | 4.52 % | 3.79 % | 3.28 % | 3.33 % | 3.28 % | 3.30 % | 2.99 % | 2.91 % | 2.57 % | 2.57 % | 2.53 % |
| Others | 27.76 % | 26.58 % | 26.81 % | 27.21 % | 26.37 % | 21.71 % | 17.78 % | 14.98 % | 14.64 % | 13.16 % | 10.27 % | 15.22 % | 10.04 % | 5.12 % | 5.04 % | 5.04 % | 5.01 % | 5.02 % | 5.06 % | 5.04 % | 4.98 % |
| No of Share Holders | 84,467 | 98,203 | 1,09,326 | 1,09,097 | 1,09,098 | 1,17,339 | 1,27,879 | 1,48,469 | 1,50,578 | 1,81,747 | 1,61,627 | 1,36,021 | 1,22,375 | 1,22,665 | 1,22,358 | 1,21,075 | 1,13,788 | 1,10,671 | 97,151 | 94,578 | 91,500 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20 | 18 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26 | 1.06 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 25 Aug 2026 |  Annual General Meeting | NA | 25 Aug 2026 | 1,898.20 | 2,277.00 |
| 16 Aug 2024 |  Dividend | ₹ 20.00 /share | 16 Aug 2024 | 1,800.25 | 1,958.25 |
| 30 Aug 2024 | Annual General Meeting | NA | 30 Aug 2024 | 1,800.25 | 1,849.00 |
| 04 Nov 2024 |  Quarterly Result Announcement | NA | 04 Nov 2024 | 1,675.30 | 1,644.85 |
| 03 Feb 2025 | Quarterly Result Announcement | NA | 03 Feb 2025 | 1,672.75 | 1,530.45 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 1,418.75 | 1,484.15 |
| 05 Aug 2025 | Quarterly Result Announcement | NA | 05 Aug 2025 | 2,000.80 | 1,982.80 |
| 14 Aug 2025 | Dividend | ₹ 18.00 /share | 14 Aug 2025 | 1,484.15 | 1,950.30 |
| 28 Aug 2025 | Annual General Meeting | NA | 28 Aug 2025 | 1,484.15 | 1,928.25 |
| 03 Nov 2025 | Quarterly Result Announcement | NA | 03 Nov 2025 | 1,917.60 | 1,928.90 |
| 28 Jan 2026 | Quarterly Result Announcement | NA | 28 Jan 2026 | 1,698.95 | 1,675.90 |
| 15 May 2026 | Quarterly Result Announcement | NA | 15 May 2026 | 1,794.40 | 1,898.20 |
Announcements
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation8 days ago
8 days agoCompliances-Reg.24(A)-Annual Secretarial ComplianceMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 18, 2026
May 18, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2026
May 16, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2026
May 15, 2026Grant Of Stock Options Under Gland Pharma Employee Stock Option Scheme 2025May 15, 2026
May 15, 2026The 48Th AGM Of The Company Will Be Held On August 25 2026May 15, 2026
May 15, 2026Board Fixes Record Date Of August 11 2026 For The Final DividendMay 15, 2026
May 15, 2026Corporate Action-Board approves DividendMay 15, 2026
May 15, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2026
May 15, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 15, 2026
May 15, 2026Q4FY26 Audited Financial ResultsMay 15, 2026
May 15, 2026Board Meeting Outcome for Outcome Of Board Meeting - 15052026May 15, 2026
May 15, 2026Announcement under Regulation 30 (LODR)-Change in DirectorateMay 14, 2026
May 14, 2026 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMay 14, 2026
May 14, 2026Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMay 14, 2026
May 14, 2026Intimation Regarding ESOP Compensation Committee MeetingMay 12, 2026
May 12, 2026Clarification With Respect To The Announcement Made On 13Th April 2026 Regarding Postal Ballot NoticeApr 27, 2026
Apr 27, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 21, 2026
Apr 21, 2026Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Financial Year Ended March 31 2026 And To Consider And Recommend Payment Of Final Dividend If Any For The Financial Year Ended March 31 2026Apr 21, 2026
Apr 21, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 14, 2026
Apr 14, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotApr 13, 2026
Apr 13, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 13, 2026
Apr 13, 2026Announcement under Regulation 30 (LODR)-Change in DirectorateApr 09, 2026
Apr 09, 2026Board Meeting Outcome for Reappointment Of Ms. Naina Lal Kidwai As An Independent Director Subject To Shareholders ApprovalApr 09, 2026
Apr 09, 2026Announcement under Regulation 30 (LODR)-Change in ManagementApr 06, 2026
Apr 06, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 04, 2026
Apr 04, 2026Closure of Trading WindowMar 27, 2026
Mar 27, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 18, 2026
Mar 18, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 13, 2026
Mar 13, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2026
Mar 11, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 09, 2026
Mar 09, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 06, 2026
Mar 06, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 04, 2026
Mar 04, 2026Announcement under Regulation 30 (LODR)-Resignation of Chief Executive Officer (CEO)Mar 03, 2026
Mar 03, 2026Announcement under Regulation 30 (LODR)-Issue of SecuritiesMar 03, 2026
Mar 03, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 25, 2026
Feb 25, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2026
Feb 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 18, 2026
Feb 18, 2026Announcement under Regulation 30 (LODR)-Change in ManagementFeb 18, 2026
Feb 18, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 06, 2026
Feb 06, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 03, 2026
Feb 03, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 01, 2026
Feb 01, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJan 29, 2026
Jan 29, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 29, 2026
Jan 29, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 28, 2026
Jan 28, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 68.18
ATR(14)
Less Volatile 87.93
STOCH(9,6)
Neutral 69.47
STOCH RSI(14)
Neutral 57.06
MACD(12,26)
Bullish 9.72
ADX(14)
Strong Trend 41.15
UO(9)
Bearish 40.81
ROC(12)
Uptrend And Accelerating 19.96
WillR(14)
Neutral -20.41
About Gland Pharma
Gland Pharma Limited is an Indian generic injectables manufacturer specializing in sterile injectables, oncology, and ophthalmic products. Founded in 1978, the company operates primarily on a B2B model, selling products in over 60 countries. It has 8 manufacturing facilities in India, including 4 for finished formulations and 3 for APIs....more
Listing Date
20 Nov, 2020(5 Years,
15 days)
Website
Chairperson NameSRINIVAS SADU
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
